Reference : Treatment of osteoporosis : where are we and where are we going to
Scientific journals : Article
Human health sciences : General & internal medicine
Treatment of osteoporosis : where are we and where are we going to
Reginster, Jean-Yves mailto [Université de Liège - ULiège > Département des sciences de la santé publique > Epidémiologie et santé publique >]
Morphologie : Bulletin de l'Association des Anatomistes
Yes (verified by ORBi)
[en] In the past years, there has been a multiplication of drugs identified as candidates for use in the prevention or the treatment of osteoporosis. When treating established osteoporosis, the objective is to prevent further skeletal deterioration, improve bone mass and/or bone microarchitecture to provide a documented reduction of the risk of vertebral and/or peripheral fractures. Calcium and vitamin D have been shown to be particularly efficient in elderly patients, mainly to prevent non-vertebral fractures. By inhibiting osteoclastic activity, calcitonin improves bone mineral density at all sites. Preliminary results suggest that it might also decrease vertebral fracture rates. Bisphosphonates have been investigated for 20 years in the treatment of osteoporosis. Alendronate was shown to reduce spinal and extravertebral fractures. New formulations of fluoride, like monofluorophosphate appear to be particularly beneficial in women with mild to moderate osteoporosis. Several new compounds, including parathormone, strontium salts, ipriflavone or others are currently developed and subject to large investigational programs to demonstrate their ability to reduce fracture.

File(s) associated to this reference

Fulltext file(s):

Restricted access
Treatment of osteoporosis where are we and where are we going to.pdfPublisher postprint678.09 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.